Aim of the work: to evaluate outcome of Concomitant Hypofractionated Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive LNs in elderly patients. Patients and methods: twenty-one patients were included diagnosed with locally advanced cancer cervix ≥ 65 years old with good performance status and adequate organ functions. Eligible patients received concomitant chemotherapy in form of cisplatin monotherapy (40 mg/m2) weekly, during radiotherapy treatment in form of External Beam Radiotherapy (EBRT) with SIB due to patients` refusal or inability to receive brachytherapy (BRT). Treatment toxicity, progression free survival (PFS) and overall survival (OS) were recorded and analyzed. Results: The median age reported was 70 years, (range: 65-76 years) and the median follow up period was 35 months (ranged from 18-47 months). The OS was 90.2% at 2 years and 76.8% at 3 years. The median time to progression was 27 months (ranged from11 – 46 months). The PFS was 75.6 % at 2 years and 63.5% at 3 years. Conclusion: in locally advanced cervical cancer, SIB-IMRT could be considered an effective and safe treatment alternative in elderly patients or unavailable brachytherapy.